Comparing the Effectiveness and Safety Associated With Infliximab vs Infliximab-abda Therapy for Patients With Hidradenitis Suppurativa
Retrospective cohort study (n=34 in US) found the proportions of patients in the biosimilar infliximab-abda and originator infliximab treatment groups achieving a Hidradenitis Suppurativa Clinical Response were not significantly different (71% vs. 60%, respectively, p=0.47).
Source:
JAMA Dermatology
SPS commentary:
This is one of two studies in JAMA Dermatology assessing biosimilars of tumor necrosis factor blockers. A Danish cohort study (n=726) found no difference in drug retention before and after nationwide switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis (1-year drug retention rates 92.1% vs. 92.0%, respectively). An editorial from a US perspective notes that inroads in the US market have been limited due to the complex interactions among pharmaceutical companies, insurers, and pharmacy benefit managers.